Wang TL - Search Results

1

Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis.

Wang Y, Huang P, Wang BG, Murdock T, Cope L, Hsu FC, Wang TL, Shih IM. Wang Y, et al. Among authors: wang bg, wang tl. Cancer Res. 2022 Dec 16;82(24):4528-4541. doi: 10.1158/0008-5472.CAN-22-1620. Cancer Res. 2022. PMID: 36206311 Free PMC article.

2

Identifying tumor origin using a gene expression-based classification map.

Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih IeM. Buckhaults P, et al. Among authors: wang tl. Cancer Res. 2003 Jul 15;63(14):4144-9. Cancer Res. 2003. PMID: 12874019

3

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.

Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IeM. Ho CL, et al. Among authors: wang tl. Cancer Res. 2004 Oct 1;64(19):6915-8. doi: 10.1158/0008-5472.CAN-04-2067. Cancer Res. 2004. PMID: 15466181

4

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM. Hsu CY, et al. Among authors: wang bg, wang tl. Clin Cancer Res. 2004 Oct 1;10(19):6432-6. doi: 10.1158/1078-0432.CCR-04-0893. Clin Cancer Res. 2004. PMID: 15475429

5

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IeM. Singer G, et al. Among authors: wang tl. Am J Surg Pathol. 2005 Feb;29(2):218-24. doi: 10.1097/01.pas.0000146025.91953.8d. Am J Surg Pathol. 2005. PMID: 15644779

6

Apolipoprotein E is required for cell proliferation and survival in ovarian cancer.

Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IeM. Chen YC, et al. Among authors: wang tl. Cancer Res. 2005 Jan 1;65(1):331-7. Cancer Res. 2005. PMID: 15665311

7

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.

Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IeM. Pohl G, et al. Among authors: wang tl. Cancer Res. 2005 Mar 1;65(5):1994-2000. doi: 10.1158/0008-5472.CAN-04-3625. Cancer Res. 2005. PMID: 15753399

8

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.

Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM. Yen MJ, et al. Among authors: wang tl. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31. doi: 10.1158/1078-0432.CCR-05-1397. Clin Cancer Res. 2006. PMID: 16467095

9

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.

Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IeM. Nakayama K, et al. Among authors: wang tl. Cancer Biol Ther. 2006 Jul;5(7):779-85. doi: 10.4161/cbt.5.7.2751. Epub 2006 Jul 26. Cancer Biol Ther. 2006. PMID: 16721043

10

Notch3 gene amplification in ovarian cancer.

Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM, Wang TL. Park JT, et al. Among authors: wang tl. Cancer Res. 2006 Jun 15;66(12):6312-8. doi: 10.1158/0008-5472.CAN-05-3610. Cancer Res. 2006. PMID: 16778208

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

785 results

Search Page